论文部分内容阅读
目的:探究131I治疗甲亢后导致甲减的危险因素,并进行分析。方法:选取我院2010年12月-2012年12月门诊及住院部78例甲亢行131I治疗后发生甲减的患者为研究对象,将其按照治疗后是否发生甲减的情况分为观察组和对照组,其中观察组38例患者治疗后发生甲减,对照组40例患者治疗后未发生甲减,对两组患者的临床治疗资料进行回顾性的分析比较。结果:131I治疗甲亢后,观察组患者TRAb升高率为84.21%,对照组患者TRAb升高率为57.50%,两组患者TRAb升高及降低情况比较X2=6.6010(P=0.0102),血清TGAb浓度的比较t=7.2103(P=0.0000),血清TPOAb浓度的比较t=2.6023(P=0.0111),差异具有统计学意义。结论:临床甲亢患者采用131I治疗后发生甲减的因素种类多,根据患者TRAb、TPO以及TM(前后需要统一,前文中为TGAb)情况进行剂量的调整,能够减低甲减的发生率,提高患者生活质量。
Objective: To explore the risk factors of hypothyroidism after 131I treatment of hyperthyroidism and analyze. Methods: From December 2010 to December 2012 in our hospital, 78 cases of hyperthyroidism patients with hypothyroidism after 131I treatment of patients at the outpatient and inpatient department as the research object, according to whether the occurrence of hypothyroidism after treatment were divided into observation group and In the control group, 38 patients in the observation group developed hypothyroidism after treatment, 40 patients in the control group did not have hypothyroidism after treatment, and the clinical treatment data of the two groups were retrospectively analyzed and compared. Results: After the treatment of hyperthyroidism with 131I, the increase rate of TRAb was 84.21% in the observation group and 57.50% in the control group. The increase and decrease of TRAb in both groups were X2 = 6.6010 (P = 0.0102) The comparison of t = 7.2103 (P = 0.0000), TPOAb serum concentration t = 2.6023 (P = 0.0111), the difference was statistically significant. CONCLUSIONS: There are many factors of hypothyroidism in patients with clinical hyperthyroidism after 131I treatment. The adjustment of dose according to TRAb, TPO and TM (before and after unification, before TGAb) can reduce the incidence of hypothyroidism and improve patients Quality of Life.